Physician profile
Harsimran Singh
NPI 1801878962
$9,523.64
in general payments reported to CMS, 2019-2025
40 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $1,636 · 2021: $2,771 · 2022: $1,055 · 2023: $723 · 2024: $751 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,204.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,156.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,041.52 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.30 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $642.01 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $528.44 | 2021-2024 | Ubrelvy, Synthroid, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $480.59 | 2019-2024 | |
| Amgen INC. | $411.71 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Pfizer INC. | $394.11 | 2019-2025 | |
| Abbott Laboratories | $353.54 | 2019-2025 | Freestyle Libre 3, Octrode |
| Lilly USA, LLC | $326.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Endologix LLC | $301.60 | 2025 | Endocross Device, Torus Stent Graft System |
| Janssen Pharmaceuticals, INC | $235.20 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $223.73 | 2019-2021 | |
| Exact Sciences Corporation | $160.23 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsimran Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.